Luye Pharma Group (FRA:LUP) Cash per Share: €0.23 (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:LUP Luye Pharma Group Ltd FRA:LUP
51 GF Score
Price €0.23
GF Value €0.34
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Luye Pharma Group Cash per Share?

Luye Pharma Group FRA:LUP +5.56% 51 Cash per Share is €0.23 as of Dec. 2025. GuruFocus rates FRA:LUP with a GF Score™ of 51/100 and a GF Value™ of €0.34 (Possible Value Trap). The stock has 5 warning signs investors should review.

Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities divided by Shares Outstanding (EOP). Luye Pharma Group's Cash per Share for the quarter that ended in Dec. 2025 was €0.23.

Luye Pharma Group  (FRA:LUP) Cash per Share Explanation

Cash per Share represents the liquidity of a compant's assets. A high level of Cash per Share suggests that there's enough money on hand for a company to cover any emergencies and that the company has adequate money to reinvest its business or pay dividends to investors. However, if the ratio is too high, it can also suggeust the inefficiency of management for not making a full usage of the cash.

Luye Pharma Group Cash per Share Related Terms

Luye Pharma Group Cash per Share Historical Data

* Premium members only.

The historical data trend for Luye Pharma Group's Cash per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Luye Pharma Group Cash per Share Chart

Luye Pharma Group Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cash per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.22 0.22 0.21 0.23 0.23

Luye Pharma Group Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Cash per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.21 0.22 0.23 0.28 0.23
FRA:LUP
51GF Score
Luye Pharma Group Ltd FRA:LUP
Cash per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Luye Pharma Group Cash per Share Calculation

This is the ratio of a company's available cash, including easy to liquidate short-term investment, to its total number of shares outstanding. The result indicates the percentage of a company's share price that is available to spend on company's activities, such as strengthening the business, paying down the debt and making dividend payment to shareholders. It's a reliable indicator of a company's financial health.

Luye Pharma Group's Cash per Share for the fiscal year that ended in Dec. 2025 is calculated as:

Cash per Share= Cash, Cash Equivalents, Marketable Securities /Shares Outstanding (EOP)
=908.794/3,994.5
=0.23

Luye Pharma Group's Cash per Share for the quarter that ended in Dec. 2025 is calculated as:

Cash per Share= Cash, Cash Equivalents, Marketable Securities /Shares Outstanding (EOP)
=908.794/3,994.5
=0.23

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Cash per Share →
What does a Cash per Share of €0.23 mean?
Luye Pharma Group (FRA:LUP) has a Cash per Share of €0.23 as of Dec. 2025. Cash per share is the per-share value of a company's available cash. View historical data for Luye Pharma Group and its competitors.
Is Luye Pharma Group's Cash per Share too high?
Luye Pharma Group's current Cash per Share is €0.23. Overall, Luye Pharma Group has a GF Score™ of 51/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Luye Pharma Group's Cash per Share compare to ZTS?
Luye Pharma Group's Cash per Share of €0.23 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash per Share for a Drug Manufacturers company?
A good Cash per Share depends on the Drug Manufacturers industry context. However, Cash per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash per Share mean?
A high Cash per Share can signal that a stock is expensive relative to its fundamentals. Cash per share is the per-share value of a company's available cash. View historical data for Luye Pharma Group and its competitors. Luye Pharma Group's current Cash per Share is €0.23. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Luye Pharma Group stock overvalued right now?
Based on GuruFocus' analysis, Luye Pharma Group (FRA:LUP) is currently considered Possible Value Trap. The stock's GF Value™ is €0.34, compared to a current price of €0.23 — trading 32.9% below its estimated fair value. The current Cash per Share is €0.23. Luye Pharma Group's overall GF Score™ is 51/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash per Share calculated?
Cash per Share is calculated from a company's financial statements. For Luye Pharma Group (FRA:LUP), the current Cash per Share is €0.23 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Luye Pharma Group (FRA:LUP) Overvalued in 2026?

Based on GuruFocus' analysis, Luye Pharma Group stock appears to be undervalued. The current stock price of €0.23 is trading 32.9% below its estimated GF Value™ of €0.34. GuruFocus considers Luye Pharma Group to be Possible Value Trap.

Key valuation signals for FRA:LUP:

  • Cash per Share: €0.23
  • GF Value™: €0.34 vs. price of €0.23 (32.9% below fair value)
  • GF Score™: 51/100 with 5 warning signs

No single metric tells the full story. See the FRA:LUP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Luye Pharma Group Business Description

Other Exchanges LYPHF:USA02186:Hong Kong
Address Hongqiao Road 1438, 22nd Floor, Gubei International Fortune Center II, Changning District, Shanghai, CHN
Luye Pharma Group Ltd is a China-based drug manufacturer that focuses on development, production, marketing and sale of pharmaceutical products. The company develops drugs related to diagnosing and treating cancer, the cardiovascular system, the alimentary tract, and the central nervous system. The company develops drugs for world-wide use in Asia, Europe, and the United States. The Group organizes its business segments by type of products. Oncology drugs, which derives maximum revenue; Cardiovascular system drugs; Alimentary tract and metabolism drugs; Central nervous system drugs; and others. Geographically, the group derives maximum revenue from Chinese Mainland, while it also has its presence in Asia (other than the Chinese mainland), European Union, and Other countries.
51GF Score

Get the complete analysis for FRA:LUP

Cash per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.23
Price
€0.34
GF Value